The approval of the first drug treatment for fatty liver disease scarring that does not require a surgical biopsy leaves the market wide open for diagnostic imaging devices.
The FDA approved the first drug for patients with moderate to advanced liver scarring (fibrosis) from MASH (metabolic dysfunction-associated steatohepatitis)...